ImmuPharma plc (LON:IMM – Get Free Report) fell 12.2% on Thursday . The company traded as low as GBX 5.84 and last traded at GBX 6.50. 9,235,788 shares were traded during mid-day trading, an increase of 16% from the average session volume of 7,959,112 shares. The stock had previously closed at GBX 7.40.
ImmuPharma Stock Down 12.2%
The firm has a market capitalization of £32.68 million, a P/E ratio of -7.30 and a beta of 1.53. The firm has a 50 day moving average of GBX 10.72 and a 200-day moving average of GBX 5.88.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- How to Use the MarketBeat Stock Screener
- Amazon Enters Correction Zone—Time to Panic, or to Load Up?
- Golden Cross Stocks: Pattern, Examples and Charts
- Tesla Just Got Called a “Must Own” Stock—Here’s Why
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Why Gold Loves Trump as Much as Trump Loves Gold
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
